Twist1 is also suggested to be a useful biomarker for predicting resistance to doxorubicin (Li et al. 2009), used widely for adjuvant chemotherapy of breast cancer (Demir et al. 2019). The gene discussed is TWIST1; the disease is breast carcinoma.